Maxvax Biotechnology Ltd.

Large funding rounds backed by both venture capital (VC) and private equity (PE) firms have recently reappeared in the China biotech space, suggested a recovery in the financing environment. Hangzhou-

Venture Capital and private equity investors in February rekindled their enthusiasm for late-stage financing rounds to carry Chinese biotechs through a persistent funding crunch. The turnaround seemed

China’s first homegrown vaccine for herpes zoster (shingles), Ganwei, developed by Changchun BCHT Biotechnology Co. (BCHT), had a strong commercial launch in 2023, setting the stage for a showdown w

As the end of the year approached, Chinese biotechs focused on the development of gene therapies and RNA-based technologies continued to win investors’ favor despite an ongoing downturn in the sector.